Lenalidomide interferes with Tumor-Promoting properties of Nurse-Like cells in chronic lymphocytic leukemia

Haematologica

Volumn 100, Issue 2, 2015, Pages 253-262

  Fiorcari, Stefania ^a   Martinelli, Silvia ^a   Bulgarelli, Jenny ^a   Audrito, Valentina ^b   Zucchini, Patrizia ^a   Colaci, Elisabetta ^a   Potenza, Leonardo ^a   Narni, Franco ^a   Luppi, Mario ^a   Deaglio, Silvia ^b   Marasca, Roberto ^a   Maffei, Rossana ^a  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; CD14 ANTIGEN; CD163 ANTIGEN; GUANOSINE TRIPHOSPHATASE; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 8; LENALIDOMIDE; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MONOCYTE CHEMOTACTIC PROTEIN 1; PHARMACOLOGY; RAC1 PROTEIN; RAP1 PROTEIN; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; SCATTER FACTOR; SOMATOMEDIN C RECEPTOR; STROMAL CELL DERIVED FACTOR 1; THALIDOMIDE; TUMOR MARKER;

ACTIN FILAMENT; ACTIN POLYMERIZATION; ANALOGS AND DERIVATIVES; APOPTOSIS; ARTICLE; CELL ACTIVATION; CELL ADHESION; CELL ADHESION ASSAY; CELL DIFFERENTIATION; CELL MIGRATION; CELL MOTION; CELL PROLIFERATION; CELLS BY BODY ANATOMY; CHEMOTAXIS ASSAY; CHRONIC LYMPHATIC LEUKEMIA; COCULTURE; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG EFFECTS; DRUG THERAPY; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOPHENOTYPING; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LYMPHOCYTE ACTIVATION; MACROPHAGE; METABOLISM; MONOCYTE; MTT ASSAY; NURSE LIKE CELLS; PATHOLOGY; PHAGOCYTOSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; T LYMPHOCYTE; TUMOR CELL CULTURE; TUMOR MICROENVIRONMENT; WESTERN BLOTTING;

ACTIN CYTOSKELETON; ANALOGS AND DERIVATIVES; ANGIOGENESIS INHIBITORS; APOPTOSIS; BLOTTING, WESTERN; CELL ADHESION; CELL MOVEMENT; CELL PROLIFERATION; COCULTURE TECHNIQUES; DRUG EFFECTS; DRUG THERAPY; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETICS; HUMANS; IMMUNOPHENOTYPING; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LYMPHOCYTE ACTIVATION; MACROPHAGES; METABOLISM; MONOCYTES; PATHOLOGY; PHAGOCYTOSIS; PHARMACOLOGY; THALIDOMIDE; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL; TUMOR MICROENVIRONMENT;

EID: 84964301380     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2014.113217     Document Type: Article

References (50)

1. Cutucache CE. Tumor-induced host immunosuppression: special focus on CLL. Int Immunopharmacol. 2013;17(1):35-41.
2. Ramsay AG, Johnson AJ, Lee AM, et al. Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug. J Clin Invest. 2008;118(7):2427-2437.
3. Filip AA, Cisel B, Koczkodaj D, Wasik-Szczepanek E, Piersiak T, Dmoszynska A. Circulating microenvironment of CLL: are nurse-like cells related to tumor-associated macrophages? Blood Cells Mol Dis. 2013; 50(4):263-270.
4. Tsukada N, Burger JA, Zvaifler NJ, Kipps TJ. Distinctive features of "nurselike" cells that differentiate in the context of chronic lym-phocytic leukemia. Blood. 2002; 99(3):1030-1037.
5. Ysebaert L, Fournie JJ. Genomic and pheno-typic characterization of nurse-like cells that promote drug resistance in chronic lymphocytic leukemia. Leuk Lymphoma. 2011;52(7):1404-1406.
6. Jia L, Clear A, Liu FT, Matthews J, et al. Extracellular HMGB1 promotes differentiation of nurse-like cells in chronic lympho-cytic leukemia. Blood. 2014;123(11):1709-1719.
7. Giannoni P, Pietra G, Travaini G, et al. Chronic lymphocytic leukemia nurse-like cells express hepatocyte growth factor receptor (c-MET) and indoleamine 2,3-dioxygenase and display features of immunosuppressive type 2 skewed macrophages. Haematologica. 2014; 99(6):1078-1087.
8. Bhattacharya N, Diener S, Idler IS, et al. Nurse-like cells show deregulated expression of genes involved in immunocompe-tence. Br J Haematol. 2011;154(3):349-356.
9. Burger JA. Nurture versus nature: the microenvironment in chronic lymphocytic leukemia. Hematology Am Soc Hematol Educ Program. 2011;2011:96-103.
10. Badoux XC, Keating MJ, Wen S, et al. Lenalidomide as initial therapy of elderly patients with chronic lymphocytic leukemia. Blood. 2011;118(13):3489-3498.
11. Ferrajoli A, Lee BN, Schlette EJ, et al. Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia. Blood. 2008;111(11):5291-5297.
12. Chen CI, Bergsagel PL, Paul H, et al. Single-agent lenalidomide in the treatment of previously untreated chronic lymphocytic leukemia. J Clin Oncol. 2011;29(9):1175-1181.
13. Kotla V, Goel S, Nischal S, et al. Mechanism of action of lenalidomide in hematological malignancies. J Hematol Oncol. 2009;2:36.
14. Gorgun G, Ramsay AG, Holderried TA, et al. E(mu)-TCL1 mice represent a model for immunotherapeutic reversal of chronic lymphocytic leukemia-induced T-cell dysfunction. Proc Natl Acad Sci USA. 2009; 106(15):6250-6255.
15. Ramsay AG, Clear AJ, Fatah R, Gribben JG. Multiple inhibitory ligands induce impaired T-cell immunologic synapse function in chronic lymphocytic leukemia that can be blocked with lenalidomide: establishing a reversible immune evasion mechanism in human cancer. Blood. 2012;120(7):1412-1421.
16. Ramsay AG, Evans R, Kiaii S, Svensson L, Hogg N, Gribben JG. Chronic lymphocytic leukemia cells induce defective LFA-1-directed T-cell motility by altering Rho GTPase signaling that is reversible with lenalidomide. Blood. 2013;121(14):2704-2714.
17. Schulz A, Durr C, Zenz T, et al. Lenalidomide reduces survival of chronic lymphocytic leukemia cells in primary cocultures by altering the myeloid microen-vironment. Blood. 2013;121(13):2503-2511.
18. Burger JA, Tsukada N, Burger M, Zvaifler NJ, Dell'Aquila M, Kipps TJ. Blood-derived nurse-like cells protect chronic lymphocytic leukemia B cells from spontaneous apopto-sis through stromal cell-derived factor-1. Blood. 2000;96(8):2655-2663.
19. Chen N, Lau H, Kong L, et al. Pharmacokinetics of lenalidomide in subjects with various degrees of renal impairment and in subjects on hemodialysis. J Clin Pharmacol. 2007; 47(12):1466-1475.
20. Fiorcari S, Brown WS, McIntyre BW, et al. The PI3-kinase delta inhibitor idelalisib (GS-1101) targets integrin-mediated adhesion of chronic lymphocytic leukemia (CLL) cell to endothelial and marrow stro-mal cells. PLoS One. 2013; 8(12):e83830.
21. Maffei R, Bulgarelli J, Fiorcari S, et al. The monocytic population in chronic lympho-cytic leukemia shows altered composition and deregulation of genes involved in phagocytosis and inflammation. Haematologica. 2013;98(7):1115-1123.
22. Maffei R, Fiorcari S, Bulgarelli J, et al. Physical contact with endothelial cells through beta1- and beta2- integrins rescues chronic lymphocytic leukemia cells from spontaneous and drug-induced apoptosis and induces a peculiar gene expression profile in leukemic cells. Haematologica. 2012;97(6):952-960.
23. Arruga F, Gizdic B, Serra S, et al. Functional impact of NOTCH1 mutations in chronic lymphocytic leukemia. Leukemia. 2014; 28(5):1060-1070.
24. Xu Y, Li J, Ferguson GD, et al. Immunomodulatory drugs reorganize cytoskeleton by modulating Rho GTPases. Blood. 2009;114(2):338-345.
25. De Luisi A, Ferrucci A, Coluccia AM, et al. Lenalidomide restrains motility and overangiogenic potential of bone marrow endothelial cells in patients with active multiple myeloma. Clin Cancer Res. 2011;17(7):1935-1946.
26. Troeger A, Johnson AJ, Wood J, et al. RhoH is critical for cell-microenvironment interactions in chronic lymphocytic leukemia in mice and humans. Blood. 2012; 119(20):4708-4718.
27. Riches JC, Sangaralingam A, Kiaii S, et al. Impact of Lenalidomide on Gene Expression Profiles of Malignant and Immune Cells in Patients with Chronic Lymphocytic Leukemia. Blood. 2011; 118(21):446-452.
28. Deaglio S, Vaisitti T, Bergui L, et al. CD38 and CD100 lead a network of surface receptors relaying positive signals for B-CLL growth and survival. Blood. 2005; 105(8):3042-3050.
29. Vicente-Manzanares M, Sanchez-Madrid F. Role of the cytoskeleton during leukocyte responses. Nat Rev Immunol. 2004; 4(2):110-122.
30. Rougerie P, Delon J. Rho GTPases: masters of T lymphocyte migration and activation. Immunol Lett. 2012;142(1-2):1-13.
31. D'Souza-Schorey C, Boettner B, Van Aelst L. Rac regulates integrin-mediated spreading and increased adhesion of T lymphocytes. Mol Cell Biol. 1998;18(7):3936-3946.
32. Bos JL, de Rooij J, Reedquist KA. Rap1 signalling: adhering to new models. Nat RevMol Cell Biol. 2001;2(5):369-377.
33. Hattori M, Minato N. Rap1 GTPase: functions, regulation, and malignancy. J Biochem. 2003;134(4):479-484.
34. Kortholt A, Bolourani P, Rehmann H, et al. A Rap/phosphatidylinositol 3-kinase pathway controls pseudopod formation [corrected]. Mol Biol Cell. 2010;21(6):936-945.
35. Boulter E, Grall D, Cagnol S, Van Obberghen-Schilling E. Regulation of cell-matrix adhesion dynamics and Rac-1 by integrin linked kinase. FASEB J. 2006; 20(9):1489-1491.
36. Qin J, Wu C. ILK: a pseudokinase in the center stage of cell-matrix adhesion and signaling. Curr Opin Cell Biol. 2012;24(5):607-613.
37. Allen WE, Zicha D, Ridley AJ, Jones GE. A role for Cdc42 in macrophage chemotaxis. J Cell Biol. 1998;141(5):1147-1157.
38. Ohba Y, Ikuta K, Ogura A, et al. Requirement for C3G-dependent Rap1 activation for cell adhesion and embryoge-nesis. EMBO J. 2001;20(13):3333-3341.
39. Williams HC, San Martin A, Adamo CM, et al. Role of coronin 1B in PDGF-induced migration of vascular smooth muscle cells. Circ Res. 2012;111(1):56-65.
40. Clanchy FI, Holloway AC, Lari R, Cameron PU, Hamilton JA. Detection and properties of the human proliferative monocyte subpopu-lation. J Leukoc Biol. 2006;79(4):757-766.
41. Burgess M, Cheung C, Chambers L, et al. CCL2 and CXCL2 enhance survival of primary chronic lymphocytic leukemia cells in vitro. Leuk Lymphoma. 2012;53(10):1988-1998.
42. Schulz A, Toedt G, Zenz T, Stilgenbauer S, Lichter P, Seiffert M. Inflammatory cytokines and signaling pathways are associated with survival of primary chronic lymphocytic leukemia cells in vitro: a dominant role of CCL2. Haematologica. 2011; 96(3):408-416.
43. Yaktapour N, Ubelhart R, Schuler J, et al. Insulin-like growth factor-1 receptor (IGF1R) as a novel target in chronic lym-phocytic leukemia. Blood. 2013; 122(9):1621-1633.
44. Chung J, Serezani CH, Huang SK, et al. Rap1 activation is required for Fc gamma receptor-dependent phagocytosis. J Immunol. 2008; 181(8):5501-5509.
45. Martinez FO, Gordon S, Locati M, Mantovani A. Transcriptional profiling of the human monocyte-to-macrophage differentiation and polarization: new molecules and patterns of gene expression. J Immunol. 2006;177(10):7303-7311.
46. Wang XF, Wang HS, Wang H, et al. The role of indoleamine 2,3-dioxygenase (IDO) in immune tolerance: focus on macrophage polarization of THP-1 cells. Cell Immunol. 2014;289(1-2):42-8.
47. Munn DH, Mellor AL. Indoleamine 2,3-dioxygenase and tumor-induced tolerance. J Clin Invest. 2007;117(5):1147-1154.
48. Akila P, Prashant V, Suma MN, Prashant SN, Chaitra TR. CD163 and its expanding functional repertoire. Clin Chim Acta. 2012;413(7-8):669-674.
49. di Celle PF, Carbone A, Marchis D, et al. Cytokine gene expression in B-cell chronic lymphocytic leukemia: evidence of constitutive interleukin-8 (IL-8) mRNA expression and secretion of biologically active IL-8 protein. Blood. 1994;84(1):220-228.
50. Yan XJ, Dozmorov I, Li W, Yancopoulos S, Sison C, Centola M, et al. Identification of outcome-correlated cytokine clusters in chronic lymphocytic leukemia. Blood. 2011;118(19):5201-5210.